Get the Daily Brief
Latest Biotech News
Nchroma wins Hong Kong clearance for HBV candidate CRMA‑1001 — First‑in‑human trial set
Nchroma Bio received clinical trial authorization in Hong Kong to start a first‑in‑human Phase I/II study of CRMA‑1001 for chronic hepatitis B virus infection, with dosing expected early next...
Yarrow picks GenSci TSHR asset: $1.37B ex‑China deal
Yarrow Bioscience agreed to license ex‑China rights to GS‑098, a thyroid‑stimulating hormone receptor (TSHR) antibody developed by Shanghai Scizeng/GenSci, in a deal that could be worth roughly...
Sanofi licenses ADEL’s tau antibody — $80M now, $1.04B possible
Sanofi struck a global licensing agreement for ADEL‑Y01, a tau‑targeting monoclonal antibody from ADEL Inc., paying $80 million upfront and up to $1.04 billion in total biobucks. The candidate is...
Bristol Myers taps Harbour BioMed: antibody discovery pact up to $1.1B
Bristol Myers Squibb signed a multiyear research and discovery collaboration with Harbour BioMed to accelerate antibody discovery and development, with potential payments that can reach $1.1...
AI drug R&D draws cash: Chai $130M Series B; Valinor $13M seed
Two AI‑focused startups raised fresh capital to scale computational drug discovery and trial design. Chai Discovery closed a $130 million Series B to expand Chai‑2, its de‑novo antibody generative...
Addition Therapeutics emerges with gene‑insertion tech and $100M+
Addition Therapeutics, a UC‑Berkeley spinout, surfaced from stealth with more than $100 million in financing to back a new RNA‑based gene insertion approach (branded as PRINT in some coverage)....
FDA eases RWE bar for devices: lower need for patient‑level records
The U.S. Food and Drug Administration said it will take a less restrictive approach to real‑world evidence for device premarket applications, allowing sponsors to use large datasets that lack...
Biosecure Act edges toward law: supply‑chain and data curbs loom
Legislation modeled in the Biosecure Act advanced in the 2026 National Defense Authorization Act, putting a congressional structure in place to bar certain federal funds from flowing to foreign...
FDA greenlights GSK’s depemokimab: long‑acting add‑on for asthma
The FDA approved depemokimab, an anti‑inflammatory biologic from GSK, as an add‑on treatment for patients aged 12 and older with certain severe asthma indications. GSK projects peak sales in the...
Immunome’s oral gamma‑secretase succeeds: Phase III win, NDA planned
Immunome reported positive top‑line Phase III results for its oral gamma‑secretase inhibitor, varegacestat, in progressing desmoid tumors — showing an 84% reduction in risk of progression or death...
XOMA Royalty to acquire Generation Bio: adds ctLNP and Moderna royalties
XOMA Royalty announced an agreement to acquire Generation Bio, a developer of cell‑targeted lipid nanoparticle (ctLNP) delivery technology, in a cash tender offer valued at about $4.29 per share...
Chai raises $130M Series B — AI antibody designer hits $1.3B valuation
Chai Discovery closed a $130 million Series B to accelerate development of its Chai‑2 generative platform for de novo antibody design and to expand commercialization, the company announced. The...
Immunome’s oral drug slashes progression risk — Phase 3 win in desmoid tumors
Immunome reported positive top‑line Phase 3 results for its oral gamma‑secretase inhibitor, which reduced the risk of disease progression or death by 84% versus placebo in patients with...
Kyverna to seek FDA clearance — autoimmune CAR‑T posts pivotal gains in stiff person syndrome
Kyverna Therapeutics said its patient‑specific CAR‑T therapy produced clinically meaningful improvements in mobility and stiffness in a registrational trial for stiff person syndrome, meeting the...
GSK wins FDA nod for long‑acting asthma drug — depemokimab cleared
GSK secured U.S. Food and Drug Administration approval for depemokimab as an add‑on treatment for patients aged 12 and older with certain inflammatory asthma indications, the company announced....
Yarrow inks $1.37B GenSci deal — buys ex‑China rights to TSHR antibody
Yarrow Bioscience, backed by RTW Investments, struck an ex‑China licensing and development agreement with Shanghai Scizeng Medical Technology (GenSci) for GS‑098 (YB‑101), a TSHR‑targeting...
Adaptive licenses TCR tech to Pfizer — multi‑year pact could top $890M
Adaptive Biotechnologies said it entered two agreements with Pfizer granting access to Adaptive’s immune‑receptor discovery platform and TCR‑antigen mapping data. One is a collaboration to...
Tumor‑selective mRNA: engineered SMRTS toggles cell‑selective gene expression
Researchers reported a tumor‑selective mRNA system (SMRTS) that programs modified mRNA to activate therapeutic genes selectively in cancer cells while shutting off expression in healthy cells,...
XOMA to acquire Generation Bio — royalty aggregator buys ctLNP delivery platform
XOMA Royalty announced an agreement to acquire Generation Bio in a cash tender offer and contingent value right structure, positioning XOMA to capture potential milestone and royalty streams tied...
CDC ends universal newborn hepatitis B guidance — major immunization policy shift
The U.S. Centers for Disease Control and Prevention announced it will end its longstanding guidance that all newborns should receive the hepatitis B vaccine, marking a substantial change in...